Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (Nasdaq: SLRX) has expanded its ongoing clinical trial for seclidemstat to nine trial sites, including Fox Chase Cancer Center. The trial focuses on patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas. Patient recruitment is underway, targeting safety and efficacy with three distinct patient arms. Seclidemstat, designed to inhibit the LSD1 enzyme, has shown promise in combination therapies, especially with topotecan and cyclophosphamide. Results are anticipated in 2022.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 3 p.m. ET. The presentation will cover the company's advancements in cancer therapies, with a focus on seclidemstat, currently in Phase 1/2 trials for Ewing sarcoma and hematologic cancers. Seclidemstat has received multiple designations from the FDA, demonstrating its potential in treating pediatric and other cancers. A recording of the presentation will be available post-event.

Salarius Pharmaceuticals will host a virtual event on June 21, 2021, at 2:00 PM ET to discuss its lead drug candidate, seclidemstat. This event aims to highlight the scientific basis and clinical development of seclidemstat, an oral inhibitor of lysine-specific histone demethylase 1 (LSD1), crucial in cancer progression. The event will feature industry experts and will be accessible via audio webcast. Seclidemstat is being studied for its potential in treating pediatric cancers and advanced solid tumors, including Ewing sarcoma, with several FDA designations including Fast Track and Orphan Drug.

Salarius Pharmaceuticals (Nasdaq: SLRX) has initiated a Phase 1/2 clinical trial to evaluate seclidemstat as a treatment for Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). This trial, led by Dr. Guillermo Montalban-Bravo at MD Anderson Cancer Center, aims to establish the maximum tolerated dose and assess safety when combined with azacytidine. The study follows promising preclinical results showing anti-proliferative effects of seclidemstat in blood cancers, highlighting a potential new treatment avenue for patients with limited options.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) will host a virtual KOL and investor event on June 21, 2021, at 2:00 p.m. ET, focusing on its lead drug candidate, seclidemstat. This novel oral inhibitor targets LSD1, a crucial enzyme in several cancers' development. The event will include insights from experts in epigenetics and oncology, addressing the potential of seclidemstat in treating pediatric and advanced cancers, especially Ewing sarcoma. Salarius has received FDA designations and financial support for its clinical trials.

Salarius Pharmaceuticals presented promising data from its ongoing Phase 1/2 clinical trials for its drug candidate, seclidemstat, targeting Ewing sarcoma and Advanced Solid Tumors (AST) during the ASCO Annual Meeting.

Initial drug activity was observed in patients with relapsed/refractory Ewing sarcoma and FET-rearranged sarcomas, indicating stable disease and prolonged time to progression. Seclidemstat demonstrated a manageable safety profile, with no significant hematological toxicities, and showcased potential efficacy, leading to further exploration in clinical settings.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced preliminary drug activity for its candidate, seclidemstat, observed in relapsed/refractory Ewing sarcoma and advanced solid tumors. The company shared three abstracts at the ASCO 2021 Annual Meeting, revealing a manageable safety profile and proof-of-concept activity. Key findings highlighted a recommended phase 2 dose of 900 mg BID, with patients experiencing significant tumor shrinkage. The abstracts cover ongoing trials and safety data supporting further investigation of seclidemstat.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported a net loss of $1.9 million or $0.06 per share for Q1 2021, an improvement from a loss of $2.1 million or $0.22 per share in Q1 2020. Cash and cash equivalents totaled $36.6 million, supporting the clinical trials of lead drug candidate, seclidemstat, in Ewing sarcoma and FET-rearranged sarcomas. The company has initiated the dose-expansion stage of its Phase 1/2 trial, with preliminary efficacy signals emerging. A conference call is scheduled for May 12, 2021, to discuss these results further.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and live audio webcast on May 12, 2021, at 5:00 p.m. ET to discuss its Q1 2021 financial results. The company focuses on developing new medicines for pediatric cancers and solid tumors, with its lead candidate, seclidemstat, currently in a Phase 1/2 trial for relapsed Ewing sarcoma. Salarius has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for its Ewing sarcoma program. An audio archive of the call will be available for 90 days post-event.